Meeting
2020 ASCO Virtual Scientific Program
Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.
Authors
Xiuning Le
Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Xiuning Le , Jonathan Wade Goldman , Jeffrey Melson Clarke , Nishan Tchekmedyian , Zofia Piotrowska , David Chu , Gajanan Bhat , Francois M. Lebel , Mark A. Socinski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03318939
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9514)
DOI
10.1200/JCO.2020.38.15_suppl.9514
Abstract #
9514
Poster Bd #
280
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
First Author: Jonathan N. Priantti
Poster
2019 Gastrointestinal Cancers Symposium
Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.
First Author: Aaron C. Tan
Poster
2018 ASCO Annual Meeting
A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer.
First Author: Zandong Yang
Poster
2024 ASCO Annual Meeting
Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-MET exon 14 skipping mutations (METex14).
First Author: Mariana da Rocha Almeida Brandao